New hope for Hard-to-Treat pancreatic cancer: targeted drug combo shows promise
NCT ID NCT06783140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new three-drug combination (NABPLAGEM) against a standard two-drug chemo regimen for people with advanced pancreatic cancer that has spread and carries a BRCA or PALB2 gene mutation. The trial enrolls 10 participants whose cancer worsened after initial treatment. The goal is to see if the new combo shrinks tumors more effectively and helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nab-paclitaxel, gemcitabine, and cisplatin
- What this could lead to
- If successful, this could offer a more effective second-line treatment option for people with BRCA or PALB2-mutated metastatic pancreatic cancer.
- What could go wrong
- This is a small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug combination may cause significant side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1/2 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Experimental drug hopes to boost chemo against tough pancreatic cancer